echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Beijing Shuangju Pharmaceutical Lilaglutide injection was approved clinically.

    Beijing Shuangju Pharmaceutical Lilaglutide injection was approved clinically.

    • Last Update: 2020-10-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Liraglutide is an alamide-based GLP-1 perturbation agent developed by Noor and Nord, first listed in the European Union in July 2009 and entered the Chinese market in 2011.
    blood sugar dependence promotes insulin secretion, simulates the body's own endocrine, protects islet β cells, and delays stomach emptying to reduce appetite.
    2017 Lilaglutide injections are included in the National Health Insurance Directory.
    At present, only the original Yanno and Nord's Lilaglutide injections were approved for sale, with different classifications and different processes to express the system of declaration of enterprises approved clinical has Tonghua Dongbao, Shenzhen Hanyu, Chengdu Sanno, Zhuhai Federal Pharmaceuticals and other eight.
    our company developed a unique Lilaglutide process, to achieve better consistency with the original research quality standards and processes.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.